Hasil Pencarian - Anita Giobbie‐Hurder

Perbaiki Hasil
  1. 1
    The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.

    The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. oleh Xinqi Wu, Meijun Zhu, Jonathan A Fletcher, Anita Giobbie-Hurder, F Stephen Hodi

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

    Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis oleh Rawad Elias, Anita Giobbie-Hurder, Nadine Jackson McCleary, Patrick Ott, F. Stephen Hodi, Osama Rahma

    Diterbitkan 2018-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma

    Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor... oleh Tamara A. Sussman, Mariano Severgnini, Mariano Severgnini, Anita Giobbie-Hurder, Anita Giobbie-Hurder, Philip Friedlander, Scott J. Swanson, Michael Jaklitsch, Thomas Clancy, Laura A. Goguen, David Lautz, Richard Swanson, Heather Daley, Jerome Ritz, Jerome Ritz, Glenn Dranoff, F. Stephen Hodi, F. Stephen Hodi

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma

    Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma oleh Xinqi Wu, Anita Giobbie-Hurder, Erin M. Connolly, Jingjing Li, Xiaoyun Liao, Mariano Severgnini, Jun Zhou, Scott Rodig, F. Stephen Hodi

    Diterbitkan 2018-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

    Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients oleh Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, Anita Giobbie-Hurder, Mariano Severgnini, Jun Zhou, Michael Manos, Lauren M. Eastman, Holden T. Maecker, F. Stephen Hodi

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma

    A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma oleh Nageatte Ibrahim, Elizabeth I. Buchbinder, Scott R. Granter, Scott J. Rodig, Anita Giobbie‐Hurder, Carla Becerra, Argyro Tsiaras, Evisa Gjini, David E. Fisher, F. Stephen Hodi

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)

    808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF) oleh Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, Osama Rahma, F Stephen Hodi, Kevin Tyan, Joanna Baginska, Martha Brainard, James Cleary, Benjamin Schlechter, Anna Maloney, Rizwan Romee

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma

    YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma oleh Thomas C. Frost, Ashley K. Gartin, Mofei Liu, Jingwei Cheng, Harita Dharaneeswaran, Derin B. Keskin, Catherine J. Wu, Anita Giobbie-Hurder, Manisha Thakuria, James A. DeCaprio

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors

    481 Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors oleh Michael Manos, Patrick Ott, Anita Giobbie-Hurder, Osama Rahma, Nicole LeBoeuf, Kevin Tyan, Ai-Tram Bui, Isaac Klein, Leyre Zubiri, Kerry Reynolds, Shilpa Grover, Gerald Weinhouse

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Qigong Mind-Body Exercise as a Biopsychosocial Therapy for Persistent Post-Surgical Pain in Breast Cancer: A Pilot Study

    Qigong Mind-Body Exercise as a Biopsychosocial Therapy for Persistent Post-Surgical Pain in Breast Cancer: A Pilot Study oleh Kamila Osypiuk MS, Jennifer Ligibel MD, Anita Giobbie-Hurder MS, Gloria Vergara-Diaz MD, Paolo Bonato PhD, Roxanne Quinn BA, Winnie Ng MA, MPH, Peter M. Wayne PhD

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

    Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial oleh Mariano Severgnini, Rizwan Haq, Anita Giobbie-Hurder, Scott J Rodig, Patrick A Ott, Evisa Gjini, Ryan J Sullivan, Donald P Lawrence, Matthew Nazzaro, Kathleen L Pfaff, Jacquelyn O Wolff, Elizabeth I Buchbinder

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

    Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab oleh David Liu, F Stephen Hodi, Rizwan Haq, Anita Giobbie-Hurder, Ann W Silk, Patrick A Ott, Tamara A Sussman, Elizabeth I Buchbinder, Anna K Maloney, Nikita Katukota, Miklos C Fogarasi, Megan Insco

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors

    Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors oleh Ai-Tram N. Bui, Kevin Tyan, Anita Giobbie-Hurder, Isaac A. Klein, Michael P. Manos, Leyre Zubiri, Kerry Reynolds, Shilpa Grover, Gerald L. Weinhouse, Patrick A. Ott, Nicole R. LeBoeuf, Osama Rahma

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

    Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors oleh Howard Streicher, Elad Sharon, Mariano Severgnini, Michael Manos, Anita Giobbie-Hurder, F Stephen Hodi, Andrew S Brohl, Philippe L Bedard, Kevin Tyan, Scott Rodig, Osama E Rahma, Daniel J Renouf, Emma Hathaway, Rachel Cunningham

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade

    Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade oleh Elizabeth I. Buchbinder, Jason L. Weirather, Michael Manos, Brian J. Quattrochi, Lynette M. Sholl, Ryan C. Brennick, Peter Bowling, Nancy Bailey, Lisa Magarace, Patrick A. Ott, Rizwan Haq, Benjamin Izar, Anita Giobbie‐Hurder, F. Stephen Hodi

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Survival outcomes in patients with de novo metastatic Merkel cell carcinoma according to site of metastases

    Survival outcomes in patients with de novo metastatic Merkel cell carcinoma according to site of metastases oleh Karam Khaddour, Karam Khaddour, Karam Khaddour, Mofei Liu, Emily Y. Kim, Emily Y. Kim, Furkan Bahar, Matheus M. Lôbo, Matheus M. Lôbo, Anita Giobbie-Hurder, Ann W. Silk, Ann W. Silk, Ann W. Silk, Manisha Thakuria, Manisha Thakuria, Manisha Thakuria

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma

    Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma oleh Gabriel J. Starrett, Manisha Thakuria, Tianqi Chen, Christina Marcelus, Jingwei Cheng, Jason Nomburg, Aaron R. Thorner, Michael K. Slevin, Winslow Powers, Robert T. Burns, Caitlin Perry, Adriano Piris, Frank C. Kuo, Guilherme Rabinowits, Anita Giobbie-Hurder, Laura E. MacConaill, James A. DeCaprio

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

    Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas oleh Priscilla K. Brastianos, Albert E. Kim, Anita Giobbie-Hurder, Eudocia Quant Lee, Nancy Wang, April F. Eichler, Ugonma Chukwueke, Deborah A. Forst, Isabel C. Arrillaga-Romany, Jorg Dietrich, Zachary Corbin, Jennifer Moliterno, Joachim Baehring, Michael White, Kevin W. Lou, Juliana Larson, Magali A. de Sauvage, Kathryn Evancic, Joana Mora, Naema Nayyar, Jay Loeffler, Kevin Oh, Helen A. Shih, William T. Curry, Daniel P. Cahill, Fred G. Barker, Elizabeth R. Gerstner, Sandro Santagata

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

    A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013 oleh Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. Weirather, Anita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

    Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer oleh Tanya E. Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, Ines Vaz-Luis, Leilani Anderson, Victoria Attaya, Jihye Park, Jake Conway, Meng Xiao He, Brendan Reardon, Erin Shannon, Gerburg Wulf, Laura M. Spring, Rinath Jeselsohn, Ian Krop, Nancy U. Lin, Ann Partridge, Eric P. Winer, Elizabeth A. Mittendorf, David Liu, Eliezer M. Van Allen, Sara M. Tolaney

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: